🚀 Gate Square “Gate Fun Token Challenge” is Live!
Create tokens, engage, and earn — including trading fee rebates, graduation bonuses, and a $1,000 prize pool!
Join Now 👉 https://www.gate.com/campaigns/3145
💡 How to Participate:
1️⃣ Create Tokens: One-click token launch in [Square - Post]. Promote, grow your community, and earn rewards.
2️⃣ Engage: Post, like, comment, and share in token community to earn!
📦 Rewards Overview:
Creator Graduation Bonus: 50 GT
Trading Fee Rebate: The more trades, the more you earn
Token Creator Pool: Up to $50 USDT per user + $5 USDT for the first 50 launche
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.